You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ER Negative Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Triple Negative Breast Cancer Trial in Gothenburg (Imatinib 400 MG Oral Tablet)

Not yet recruiting
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Imatinib 400 MG Oral Tablet
  • Gothenburg, Sweden
    Barbro Linderholm
Feb 1, 2023

Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer Trial in Carmel, Indianapolis

Not yet recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Carmel, Indiana
  • +2 more
Apr 27, 2023

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Assessed by 18F-FES PET/CT in MBC With ER-positive Primary Tumor

Recruiting
  • Breast Cancer
    • Shanghai, Shanghai, China
      Biyun Wang, MD
    Apr 5, 2023

    ER+ HER2- Advanced Breast Cancer Trial in Chuo-ku, Kashiwa, Koto-ku (AZD9833)

    Active, not recruiting
    • ER+ HER2- Advanced Breast Cancer
    • Chuo-ku, Japan
    • +2 more
    Jan 24, 2023

    ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer Trial in Luoyang, Shanghai (TFX06 tablet)

    Recruiting
    • ER+, HER2- Advanced Breast Cancer
    • Metastatic Breast Cancer
    • TFX06 tablet
    • Luoyang, Henan, China
    • +1 more
    Jun 25, 2023

    Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based

    Not yet recruiting
    • Breast Cancer
    • Cancer of the Breast
    • VENTANA MIB-1 Ki67 assay
    • +4 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Apr 18, 2023

    Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)

    Completed
    • Breast Neoplasms
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Oct 26, 2022

    Breast Cancer Trial (Giredestrant, Giredestrant plus triptorelin, Anastrozole plus triptorelin)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jun 13, 2023

    TNBC - Triple-Negative Breast Cancer Trial (Alkaline Glucosodiene Molecules)

    Not yet recruiting
    • TNBC - Triple-Negative Breast Cancer
    • Alkaline Glucosodiene Molecules
    • (no location specified)
    Jul 14, 2023

    Gut and Tumor Microbiome in Advanced ER-positive and

    Not yet recruiting
    • Breast Cancer
    • Melanoma
    • Observation
    • (no location specified)
    Nov 6, 2023

    Triple Negative Breast Cancer, HER2-negative Breast Cancer Trial in Tampa (HER2 - primed Dendritic cells, HER3 - primed

    Recruiting
    • Triple Negative Breast Cancer
    • HER2-negative Breast Cancer
    • HER2 - primed Dendritic cells
    • HER3 - primed Dendritic cells
    • Tampa, Florida
      Moffitt Cancer Center
    Jan 10, 2023

    Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

    Recruiting
    • Breast Cancer
    • +2 more
      • Wuhan, Hubei, China
        TongjiHospital
      Sep 12, 2022

      Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (OP-1250, Fulvestrant, Anastrozole)

      Not yet recruiting
      • Breast Cancer
      • +4 more
      • (no location specified)
      Aug 31, 2023

      Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)

      Not yet recruiting
      • Breast Cancer
      • Ovarian Function Suppression + Aromatase Inhibitor
      • Adjuvant Chemotherapy + Ovarian Function Suppression
      • (no location specified)
      May 19, 2023

      Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

      Not yet recruiting
      • Estrogen-receptor-positive Breast Cancer
      • +3 more
      • elacestrant, palbociclib, abemaciclib, ribociclib
      • Chicago, Illinois
        Northwestern University
      Sep 25, 2023

      Older Women With ER Positive, HER2 Negative Early Breast Cancer

      Enrolling by invitation
      • Breast Cancer Female
      • Translational study
      • Sutton, United Kingdom
        The Royal Marsden NHS Foundation Trust
      Feb 8, 2023

      Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

      Not yet recruiting
      • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
      • (no location specified)
      Sep 26, 2023

      ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

      Recruiting
      • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
      • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
      • Montpellier, France
      • +1 more
      Nov 16, 2022

      Advanced or Metastatic Breast Cancer Trial in Paris (Milademetan, Patient Reported Outcomes (PROs) and Health-Related Quality of

      Not yet recruiting
      • Advanced or Metastatic Breast Cancer
      • Milademetan
      • Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
      • Paris, France
        Institut Curie
      Jun 27, 2023

      Breast Cancer Trial in Sarasota, Nashville (AC699)

      Recruiting
      • Breast Cancer
      • Sarasota, Florida
      • +1 more
      Jan 3, 2023

      Immune Environment in Response to Therapy in Breast Cancer

      Recruiting
      • Breast Cancer
      • +3 more
      • Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
      • Philadelphia, Pennsylvania
        Abramson Cancer Center
      Sep 15, 2022

      Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

      Active, not recruiting
      • Breast Neoplasms
      • Chuo Ku, Japan
      • +1 more
      Dec 19, 2022

      ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer Trial in Madison, Milwaukee (Onapristone, Fulvestrant)

      Recruiting
      • ER-positive Breast Cancer
      • +2 more
      • Madison, Wisconsin
      • +1 more
      Jul 7, 2022

      Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Alpelisib, Tamoxifen, Infigratinib)

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • Stanford, California
        Stanford University
      Nov 16, 2022